MDs' reactions to pharma marketing influenced by brand, side effects: Managemen...( A study of pharmaceutical companies ...),Health
A study of pharmaceutical companies marketing to physicians shows that doctors are most influenced by brand preference and marketing that addresses the problems of drugs with many side effects, according to the Management Insights feature in the current issue of Management Science, the flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS).
Management Insights, a regular feature of the journal, is a digest of important research in business, management, operations research, and management science. It appears in every issue of the monthly journal.
The Debate on Influencing Doctors Decisions: Are Drug Characteristics the Missing Link? is by Sriram Venkataraman of Emory University and Stefan Stremersch of Duke University.
Decision making by physicians on patients treatment has come under increased public scrutiny, with debate on the effects of marketing actions of pharmaceutical firms toward physicians and their impact on physician prescription behavior. Some scholars find a strong and positive influence of marketing actions, some find only moderate effects, and others even find negative effects.
Debate is also mounting on the role of other influencers (such as patient requests) in physician decision making, both on prescriptions and sample dispensing.
In their Management Science paper, Venkataraman and Stremersch argue that one factor that may tip the balance in this debate is the role of drug characteristics, such as a drugs effectiveness and a drugs side effects. Using a unique data set, they show that marketing effortsoperationalized as detailing and symposium meetings of firms to physiciansand patient requests do affect physician decision making differentially across brands.
They also find that the responsiveness of physicians decision making to marketing efforts and patient requests depends upon the drugs effectiveness and side effects.
The current issue of Management Insights is avai
'/>"/>
| Contact: Barry List barry.list@informs.org 443-757-3560 Institute for Operations Research and the Management Sciences Source:Eurekalert |
Related medicine news :
1. London School of Hygiene to play key role in global collaboration on adverse drug reactions
2. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |